Svelta Labs
Svelta Labs science for weight, wellness and skin
Svelta Labs Journal

Svelta Labs Education & Research Journal

Fresh editorial content for peptide research, skincare science, wellbeing categories, Svelta-GPT updates, and research-use product guidance.

Obesity, Sleep Apnoea and Cancer: Revisiting an Interconnected Triad
Weight science 18 Nov 2026

Obesity, Sleep Apnoea and Cancer: Revisiting an Interconnected Triad

A captured review excerpt argues that obesity, obstructive sleep apnoea and cancer form an interconnected triad, and that oxygen-desaturation measures may predict cancer-related outcomes better than the standard apnoea-hypopnoea index.

Hair Loss Concerns with Mounjaro: A Lived Experience Perspective
Wellbeing 18 Nov 2026

Hair Loss Concerns with Mounjaro: A Lived Experience Perspective

Some users report hair loss after increasing their Mounjaro dose, raising questions about this side effect's nature and duration. This article explores the lived experience and current understanding.

What a Reddit Thread on Stomach Cramps During Weight-Loss Treatment Actually Shows
Wellbeing 15 Oct 2026

What a Reddit Thread on Stomach Cramps During Weight-Loss Treatment Actually Shows

A captured Reddit discussion about stomach cramps during weight-loss treatment offers a useful lesson in reading community experience carefully — and in separating it from verified evidence.

Semaglutide and Athletic Performance: A New Clinical Trial in Runners
Research 15 Oct 2026

Semaglutide and Athletic Performance: A New Clinical Trial in Runners

A new randomised placebo-controlled trial will examine how short-term semaglutide affects body composition, muscle function, running economy and performance in well-trained runners.

Brain Stimulation and Weight Loss: What a Phase 2 Trial Explored
Research 15 Oct 2026

Brain Stimulation and Weight Loss: What a Phase 2 Trial Explored

A registered Phase 2 study set out to test whether electrical stimulation of the dorsolateral prefrontal cortex changed food intake and weight over four weeks, alongside weight-loss counselling. Here is what the record actually describes, and what it does not.

Starting Mounjaro: Planning Support Around Everyday Life
Wellbeing

Starting Mounjaro: Planning Support Around Everyday Life

Starting Mounjaro involves more than a prescription. Explore the support, follow-up and practical questions that help people plan around everyday life.

Mounjaro Expiry Dates and Storage: Planning Your Supply
Wellbeing

Mounjaro Expiry Dates and Storage: Planning Your Supply

Printed expiry and time after first use are different limits. This guide explains how to check a Mounjaro supply without relying on old forum batch dates.

GLP-1 Medicines and Eating Behaviour: Why Responses May Differ
Slimming Pen News

GLP-1 Medicines and Eating Behaviour: Why Responses May Differ

A 92-person observational study linked external eating scores with weight change. It does not prove that emotional eaters cannot benefit from GLP-1 medicines.

Weight Regain After Stopping GLP-1 Medicines: Evidence and Support
Wellbeing

Weight Regain After Stopping GLP-1 Medicines: Evidence and Support

Experiences after stopping GLP-1 medicines vary. Clinical withdrawal studies show why weight maintenance needs continuing support rather than blame.

Mounjaro KwikPen “Golden Dose”: New Pens and Leftover Medicine
Wellbeing

Mounjaro KwikPen “Golden Dose”: New Pens and Leftover Medicine

A modified Mounjaro KwikPen can look different, but both versions deliver four fixed doses. Leftover solution is not a validated extra dose.

BRP Peptide and Appetite: What Stanford’s Animal Research Found
Weight Science

BRP Peptide and Appetite: What Stanford’s Animal Research Found

Stanford’s BRP discovery links computational peptide screening with appetite research in animals. It does not yet establish human benefit or comparative safety.

Intermittent Fasting and the Gut Microbiome: A Brain–Gut Study
Weight Science

Intermittent Fasting and the Gut Microbiome: A Brain–Gut Study

A small study tracked gut bacteria and brain activity during intermittent energy restriction. Its associations raise questions rather than establish a fasting prescription.

Wegovy Tablets UK Approval: Oral Semaglutide and Access
Research & Regulation

Wegovy Tablets UK Approval: Oral Semaglutide and Access

Wegovy tablets received UK authorisation in June 2026. Regulatory approval, actual supply and NHS funding are separate steps.

Obesity Prevention and the Food Environment: England’s Policy Debate
Wellbeing & Public Health

Obesity Prevention and the Food Environment: England’s Policy Debate

Food environments shape the choices available to people. This editorial examines Parliament’s proposed action on healthier sales, advertising and local access.

GLP-1 Side Effects: Common Symptoms and Important Safety Signals
Wellbeing

GLP-1 Side Effects: Common Symptoms and Important Safety Signals

Digestive symptoms are common with GLP-1 medicines, but some warnings are medicine-specific. Here is how to distinguish established risks from online anecdotes.

GLP-1 Medicines and Fat Graft Survival: What the Biology Suggests
Research Insights

GLP-1 Medicines and Fat Graft Survival: What the Biology Suggests

A scoping review raises questions about incretin medicines and fat graft biology. Its mechanisms are hypotheses, not proof of poorer surgical outcomes.

FDA Peptide Panel Recommendations: What a Vote Can Change
wellbeing

FDA Peptide Panel Recommendations: What a Vote Can Change

Reports of favourable peptide-panel votes raised questions about access. The key distinction is between advisory recommendations, agency action and product approval.